Restless Legs Syndrome Market, Global Outlook and Forecast 2022-2028

April 2022 | 68 pages | ID: RCAA70658783EN
Market Monitor Global

Abstracts

Restless legs syndrome (RLS) is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.

This report contains market size and forecasts of Restless Legs Syndrome in Global, including the following market information:

Global Restless Legs Syndrome Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Restless Legs Syndrome market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Pharmacological Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Restless Legs Syndrome include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co. and Jazz Pharmaceuticals, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Restless Legs Syndrome companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Restless Legs Syndrome Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Restless Legs Syndrome Market Segment Percentages, by Type, 2021 (%)

• Pharmacological Therapy
• Non-Pharmacological Therapy

Global Restless Legs Syndrome Market, by End User, 2017-2022, 2023-2028 ($ millions)

Global Restless Legs Syndrome Market Segment Percentages, by End User, 2021 (%)

• Below 35 Years Old
• From 35 to 50 Years Old
• Above 50 Years Old

Global Restless Legs Syndrome Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Restless Legs Syndrome Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Restless Legs Syndrome revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Restless Legs Syndrome revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Boehringer Ingelheim GmbH
• UCB SA
• Astellas
• Arbor Pharmaceuticals
• GlaxoSmithKline plc.
• Ligand Pharmaceuticals Incorporated
• axxonis Pharma AG
• Kyowa Hakko Kirin Co.
• Jazz Pharmaceuticals, Inc.
• Omeros Corporation
• Manhattan Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Restless Legs Syndrome Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by End User
1.3 Global Restless Legs Syndrome Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL RESTLESS LEGS SYNDROME OVERALL MARKET SIZE

2.1 Global Restless Legs Syndrome Market Size: 2021 VS 2028
2.2 Global Restless Legs Syndrome Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Restless Legs Syndrome Players in Global Market
3.2 Top Global Restless Legs Syndrome Companies Ranked by Revenue
3.3 Global Restless Legs Syndrome Revenue by Companies
3.4 Top 3 and Top 5 Restless Legs Syndrome Companies in Global Market, by Revenue in 2021
3.5 Global Companies Restless Legs Syndrome Product Type
3.6 Tier 1, Tier 2 and Tier 3 Restless Legs Syndrome Players in Global Market
  3.6.1 List of Global Tier 1 Restless Legs Syndrome Companies
  3.6.2 List of Global Tier 2 and Tier 3 Restless Legs Syndrome Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Restless Legs Syndrome Market Size Markets, 2021 & 2028
  4.1.2 Pharmacological Therapy
  4.1.3 Non-Pharmacological Therapy
4.2 By Type - Global Restless Legs Syndrome Revenue & Forecasts
  4.2.1 By Type - Global Restless Legs Syndrome Revenue, 2017-2022
  4.2.2 By Type - Global Restless Legs Syndrome Revenue, 2023-2028
  4.2.3 By Type - Global Restless Legs Syndrome Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Restless Legs Syndrome Market Size, 2021 & 2028
  5.1.2 Below 35 Years Old
  5.1.3 From 35 to 50 Years Old
  5.1.4 Above 50 Years Old
5.2 By End User - Global Restless Legs Syndrome Revenue & Forecasts
  5.2.1 By End User - Global Restless Legs Syndrome Revenue, 2017-2022
  5.2.2 By End User - Global Restless Legs Syndrome Revenue, 2023-2028
  5.2.3 By End User - Global Restless Legs Syndrome Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Restless Legs Syndrome Market Size, 2021 & 2028
6.2 By Region - Global Restless Legs Syndrome Revenue & Forecasts
  6.2.1 By Region - Global Restless Legs Syndrome Revenue, 2017-2022
  6.2.2 By Region - Global Restless Legs Syndrome Revenue, 2023-2028
  6.2.3 By Region - Global Restless Legs Syndrome Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Restless Legs Syndrome Revenue, 2017-2028
  6.3.2 US Restless Legs Syndrome Market Size, 2017-2028
  6.3.3 Canada Restless Legs Syndrome Market Size, 2017-2028
  6.3.4 Mexico Restless Legs Syndrome Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Restless Legs Syndrome Revenue, 2017-2028
  6.4.2 Germany Restless Legs Syndrome Market Size, 2017-2028
  6.4.3 France Restless Legs Syndrome Market Size, 2017-2028
  6.4.4 U.K. Restless Legs Syndrome Market Size, 2017-2028
  6.4.5 Italy Restless Legs Syndrome Market Size, 2017-2028
  6.4.6 Russia Restless Legs Syndrome Market Size, 2017-2028
  6.4.7 Nordic Countries Restless Legs Syndrome Market Size, 2017-2028
  6.4.8 Benelux Restless Legs Syndrome Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Restless Legs Syndrome Revenue, 2017-2028
  6.5.2 China Restless Legs Syndrome Market Size, 2017-2028
  6.5.3 Japan Restless Legs Syndrome Market Size, 2017-2028
  6.5.4 South Korea Restless Legs Syndrome Market Size, 2017-2028
  6.5.5 Southeast Asia Restless Legs Syndrome Market Size, 2017-2028
  6.5.6 India Restless Legs Syndrome Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Restless Legs Syndrome Revenue, 2017-2028
  6.6.2 Brazil Restless Legs Syndrome Market Size, 2017-2028
  6.6.3 Argentina Restless Legs Syndrome Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Restless Legs Syndrome Revenue, 2017-2028
  6.7.2 Turkey Restless Legs Syndrome Market Size, 2017-2028
  6.7.3 Israel Restless Legs Syndrome Market Size, 2017-2028
  6.7.4 Saudi Arabia Restless Legs Syndrome Market Size, 2017-2028
  6.7.5 UAE Restless Legs Syndrome Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Boehringer Ingelheim GmbH
  7.1.1 Boehringer Ingelheim GmbH Corporate Summary
  7.1.2 Boehringer Ingelheim GmbH Business Overview
  7.1.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Major Product Offerings
  7.1.4 Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue in Global Market (2017-2022)
  7.1.5 Boehringer Ingelheim GmbH Key News
7.2 UCB SA
  7.2.1 UCB SA Corporate Summary
  7.2.2 UCB SA Business Overview
  7.2.3 UCB SA Restless Legs Syndrome Major Product Offerings
  7.2.4 UCB SA Restless Legs Syndrome Revenue in Global Market (2017-2022)
  7.2.5 UCB SA Key News
7.3 Astellas
  7.3.1 Astellas Corporate Summary
  7.3.2 Astellas Business Overview
  7.3.3 Astellas Restless Legs Syndrome Major Product Offerings
  7.3.4 Astellas Restless Legs Syndrome Revenue in Global Market (2017-2022)
  7.3.5 Astellas Key News
7.4 Arbor Pharmaceuticals
  7.4.1 Arbor Pharmaceuticals Corporate Summary
  7.4.2 Arbor Pharmaceuticals Business Overview
  7.4.3 Arbor Pharmaceuticals Restless Legs Syndrome Major Product Offerings
  7.4.4 Arbor Pharmaceuticals Restless Legs Syndrome Revenue in Global Market (2017-2022)
  7.4.5 Arbor Pharmaceuticals Key News
7.5 GlaxoSmithKline plc.
  7.5.1 GlaxoSmithKline plc. Corporate Summary
  7.5.2 GlaxoSmithKline plc. Business Overview
  7.5.3 GlaxoSmithKline plc. Restless Legs Syndrome Major Product Offerings
  7.5.4 GlaxoSmithKline plc. Restless Legs Syndrome Revenue in Global Market (2017-2022)
  7.5.5 GlaxoSmithKline plc. Key News
7.6 Ligand Pharmaceuticals Incorporated
  7.6.1 Ligand Pharmaceuticals Incorporated Corporate Summary
  7.6.2 Ligand Pharmaceuticals Incorporated Business Overview
  7.6.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Major Product Offerings
  7.6.4 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue in Global Market (2017-2022)
  7.6.5 Ligand Pharmaceuticals Incorporated Key News
7.7 axxonis Pharma AG
  7.7.1 axxonis Pharma AG Corporate Summary
  7.7.2 axxonis Pharma AG Business Overview
  7.7.3 axxonis Pharma AG Restless Legs Syndrome Major Product Offerings
  7.7.4 axxonis Pharma AG Restless Legs Syndrome Revenue in Global Market (2017-2022)
  7.7.5 axxonis Pharma AG Key News
7.8 Kyowa Hakko Kirin Co.
  7.8.1 Kyowa Hakko Kirin Co. Corporate Summary
  7.8.2 Kyowa Hakko Kirin Co. Business Overview
  7.8.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Major Product Offerings
  7.8.4 Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue in Global Market (2017-2022)
  7.8.5 Kyowa Hakko Kirin Co. Key News
7.9 Jazz Pharmaceuticals, Inc.
  7.9.1 Jazz Pharmaceuticals, Inc. Corporate Summary
  7.9.2 Jazz Pharmaceuticals, Inc. Business Overview
  7.9.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Major Product Offerings
  7.9.4 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue in Global Market (2017-2022)
  7.9.5 Jazz Pharmaceuticals, Inc. Key News
7.10 Omeros Corporation
  7.10.1 Omeros Corporation Corporate Summary
  7.10.2 Omeros Corporation Business Overview
  7.10.3 Omeros Corporation Restless Legs Syndrome Major Product Offerings
  7.10.4 Omeros Corporation Restless Legs Syndrome Revenue in Global Market (2017-2022)
  7.10.5 Omeros Corporation Key News
7.11 Manhattan Pharmaceuticals
  7.11.1 Manhattan Pharmaceuticals Corporate Summary
  7.11.2 Manhattan Pharmaceuticals Business Overview
  7.11.3 Manhattan Pharmaceuticals Restless Legs Syndrome Major Product Offerings
  7.11.4 Manhattan Pharmaceuticals Restless Legs Syndrome Revenue in Global Market (2017-2022)
  7.11.5 Manhattan Pharmaceuticals Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Restless Legs Syndrome Market Opportunities & Trends in Global Market
Table 2. Restless Legs Syndrome Market Drivers in Global Market
Table 3. Restless Legs Syndrome Market Restraints in Global Market
Table 4. Key Players of Restless Legs Syndrome in Global Market
Table 5. Top Restless Legs Syndrome Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Restless Legs Syndrome Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Restless Legs Syndrome Revenue Share by Companies, 2017-2022
Table 8. Global Companies Restless Legs Syndrome Product Type
Table 9. List of Global Tier 1 Restless Legs Syndrome Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Restless Legs Syndrome Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Restless Legs Syndrome Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Restless Legs Syndrome Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Restless Legs Syndrome Revenue in Global (US$, Mn), 2023-2028
Table 14. By End User – Global Restless Legs Syndrome Revenue, (US$, Mn), 2021 & 2028
Table 15. By End User - Restless Legs Syndrome Revenue in Global (US$, Mn), 2017-2022
Table 16. By End User - Restless Legs Syndrome Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Restless Legs Syndrome Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Restless Legs Syndrome Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Restless Legs Syndrome Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Restless Legs Syndrome Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Restless Legs Syndrome Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Restless Legs Syndrome Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Restless Legs Syndrome Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Restless Legs Syndrome Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Restless Legs Syndrome Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Restless Legs Syndrome Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Restless Legs Syndrome Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Restless Legs Syndrome Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Restless Legs Syndrome Revenue, (US$, Mn), 2023-2028
Table 30. Boehringer Ingelheim GmbH Corporate Summary
Table 31. Boehringer Ingelheim GmbH Restless Legs Syndrome Product Offerings
Table 32. Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue (US$, Mn), (2017-2022)
Table 33. UCB SA Corporate Summary
Table 34. UCB SA Restless Legs Syndrome Product Offerings
Table 35. UCB SA Restless Legs Syndrome Revenue (US$, Mn), (2017-2022)
Table 36. Astellas Corporate Summary
Table 37. Astellas Restless Legs Syndrome Product Offerings
Table 38. Astellas Restless Legs Syndrome Revenue (US$, Mn), (2017-2022)
Table 39. Arbor Pharmaceuticals Corporate Summary
Table 40. Arbor Pharmaceuticals Restless Legs Syndrome Product Offerings
Table 41. Arbor Pharmaceuticals Restless Legs Syndrome Revenue (US$, Mn), (2017-2022)
Table 42. GlaxoSmithKline plc. Corporate Summary
Table 43. GlaxoSmithKline plc. Restless Legs Syndrome Product Offerings
Table 44. GlaxoSmithKline plc. Restless Legs Syndrome Revenue (US$, Mn), (2017-2022)
Table 45. Ligand Pharmaceuticals Incorporated Corporate Summary
Table 46. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product Offerings
Table 47. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue (US$, Mn), (2017-2022)
Table 48. axxonis Pharma AG Corporate Summary
Table 49. axxonis Pharma AG Restless Legs Syndrome Product Offerings
Table 50. axxonis Pharma AG Restless Legs Syndrome Revenue (US$, Mn), (2017-2022)
Table 51. Kyowa Hakko Kirin Co. Corporate Summary
Table 52. Kyowa Hakko Kirin Co. Restless Legs Syndrome Product Offerings
Table 53. Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue (US$, Mn), (2017-2022)
Table 54. Jazz Pharmaceuticals, Inc. Corporate Summary
Table 55. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product Offerings
Table 56. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue (US$, Mn), (2017-2022)
Table 57. Omeros Corporation Corporate Summary
Table 58. Omeros Corporation Restless Legs Syndrome Product Offerings
Table 59. Omeros Corporation Restless Legs Syndrome Revenue (US$, Mn), (2017-2022)
Table 60. Manhattan Pharmaceuticals Corporate Summary
Table 61. Manhattan Pharmaceuticals Restless Legs Syndrome Product Offerings
Table 62. Manhattan Pharmaceuticals Restless Legs Syndrome Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Restless Legs Syndrome Segment by Type in 2021
Figure 2. Restless Legs Syndrome Segment by End User in 2021
Figure 3. Global Restless Legs Syndrome Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Restless Legs Syndrome Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Restless Legs Syndrome Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Restless Legs Syndrome Revenue in 2021
Figure 8. By Type - Global Restless Legs Syndrome Revenue Market Share, 2017-2028
Figure 9. By End User - Global Restless Legs Syndrome Revenue Market Share, 2017-2028
Figure 10. By Region - Global Restless Legs Syndrome Revenue Market Share, 2017-2028
Figure 11. By Country - North America Restless Legs Syndrome Revenue Market Share, 2017-2028
Figure 12. US Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Restless Legs Syndrome Revenue Market Share, 2017-2028
Figure 16. Germany Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 17. France Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Restless Legs Syndrome Revenue Market Share, 2017-2028
Figure 24. China Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 28. India Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Restless Legs Syndrome Revenue Market Share, 2017-2028
Figure 30. Brazil Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Restless Legs Syndrome Revenue Market Share, 2017-2028
Figure 33. Turkey Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Restless Legs Syndrome Revenue, (US$, Mn), 2017-2028
Figure 37. Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. UCB SA Restless Legs Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Astellas Restless Legs Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Arbor Pharmaceuticals Restless Legs Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. GlaxoSmithKline plc. Restless Legs Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. axxonis Pharma AG Restless Legs Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Omeros Corporation Restless Legs Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Manhattan Pharmaceuticals Restless Legs Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)